MetaCap

ProKidney (PROK) vs REGENXBIO (RGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

REGENXBIO (RGNX) has outperformed ProKidney (PROK) over the past year, losing 39.3% versus a loss of 52.5%. Over five years, RGNX leads with a -76.9% price change compared with -89.5% for PROK. REGENXBIO is the larger company by market cap ($473.4 million vs $415.2 million), about 1.1 times the size, while ProKidney is growing revenue faster (+1075.0% vs +104.5%).

REGENXBIO converts more of its revenue into profit, with a net margin of -113.8% versus -7725.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PROK-52.51%RGNX-39.32%
+40%-9%-57%
Nov 21, 20251 yearNov 20, 2026
PROK-89.52%RGNX-78.63%
+37%-32%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PROK versus RGNX key metrics
MetricPROKRGNX
Share price$1.04$7.16
Market cap$415.21M$473.44M
1-day change-1.89%-0.28%
YTD return-53.57%-50.28%
1-year return-52.51%-39.32%
5-year return-89.49%-76.87%
EPS (TTM)$-0.61$-3.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$893.00K$170.44M
Revenue growth (YoY)+1075.00%+104.54%
Net income (latest FY)$-68.99M$-193.88M
Operating margin-18477.83%-94.58%
Net margin-7725.20%-113.75%
52-week high$2.65$16.19
52-week low$0.87$5.46
Distance from 52-week high-60.75%-55.78%
Analyst consensusbuystrong_buy
Avg. price target upside+525.00%+198.88%
Average volume1.44M1.39M
Shares outstanding209.63M66.12M
Employees231371
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RGNX has outperformed PROK by 13.2 percentage points over the past year.
  • REGENXBIO is more profitable, keeping -113.8 cents of every revenue dollar as net income versus -7725.2 cents for ProKidney.
  • ProKidney grew revenue faster in its latest fiscal year (+1075.00% vs +104.54%).

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

About REGENXBIO

RGNX stock →

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees

PROK vs RGNX FAQ

Which is bigger, ProKidney or REGENXBIO?

REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $415.21M for ProKidney (PROK).

Which stock has performed better over the past year, PROK or RGNX?

RGNX returned -39.32% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.

Are ProKidney and REGENXBIO in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons